SQUARE

e-

SQUARE

 
Healthcare online Keeping you up-to-date
VOL.  15     ISSUE:  1  January  2017 Medical Services Department

SQUARE Pharmaceuticals Ltd.

Features

EDITORIAL TEAM

OMAR AKRAMUR RAB

MBBS, FCGP, FIAGP,

P G Dip. Business Management

MAHFUZUR RAHMAN

 MBBS, MBA

Md. Saiful Alam

MBBS, MPH

EDITORIAL

Dear Doctor,

Happy New Year 2017 !

Welcome to our online healthcare bulletin e- SQUARE.

In this issue, we focused on some interesting features like -
"Chemo & Lung Ca !
", "Diet in Pregnant Women !", "GDM & Depression !", "Drugs & Stomach Infection !",  "Superbug !", "Surgery & Obesity !".

In our regular feature, we have some products information of SQUARE Pharmaceuticals Ltd. as well.

Please send your feedback !  We always value your comments !

On behalf of the management of SQUARE, we wish you all a very happy, healthy and prosperous life.

Click on to reply mode.

Yours sincerely,

 

Editorial Team

Reply Mode      : e-square@squaregroup.com

The views expressed in this publication do not necessarily reflect those of its editor or SQUARE Pharmaceuticals Ltd.

 Chemo & Lung Cancer !

Delaying Chemo After Lung Cancer Surgery? Better Late Than Never

Lung cancer chemotherapy that's been delayed due to slow recovery from surgery can still provide real benefit to patients. The study involved thousands of patients with non-small-cell lung cancers (NSCLC), which comprise about 90 percent of all lung tumors. Lung cancer remains the leading cancer killer in the United States. Chemotherapy is a standard part of treatment for people who've already had surgery to treat tumors that are larger than 4 centimeters or that has spread to the lymph nodes. Typically, this post-surgical chemotherapy begins within six weeks of the surgery. However, not all patients are able to tolerate chemotherapy so quickly after their operation, including those who develop surgical complications. All of the patients included in the study had stage I, II or III non-small-cell lung cancers. The lead researcher found that delaying chemotherapy -- even when administered up to four months after surgery -- didn't increase a patients' risk of death. And compared to patients who only had surgery with no follow-up chemo, those who had delayed chemotherapy still had a lower risk of death during the study period. Based on the findings, clinicians should still consider chemotherapy in appropriately selected patients who are healthy enough to tolerate it, up to four months after surgical resection. Decisions regarding post-op chemotherapy are always difficult and each case must be looked at individually. Factors such as other illnesses the patient might be battling, or his or her physical ability to deal with chemo, play into an oncologist's decision whether to administer chemotherapy and when.

SOURCE: HealthDay News, January 2017

Return to top

 Diet in Pregnant Women !

                                                     FDA Offers Guidance on Fish Intake for Kids, Pregnant Women

A new U.S. government guideline classifies fish into three categories of safety to help pregnant women, breast-feeding mothers and parents of young children make healthy choices. The 62 types of fish and shellfish included in the guideline are sorted into: best choices: eat two to three servings a week; good choices: eat one serving a week; and fish to avoid. Nearly 90 percent of fish eaten in the United States fall into the best choices category, according to the U.S. Food and Drug Administration and the U.S. Environmental Protection Agency. Fifty percent of pregnant women eat fewer than 2 ounces of fish a week, which is far less than the recommended amount, the FDA said. The FDA and EPA recommend two to three servings of lower-mercury fish per week, or 8 to 12 ounces total. Twelve ounces is the recommended maximum weekly consumption, according to the new guidelines. Lower-mercury fish and shellfish, part of the best choices group, include some of the most commonly eaten varieties, such as shrimp, pollock, salmon, canned light tuna, tilapia, catfish and cod. The FDA and EPA recommend only one serving per week of fish from the good choices category, which includes bluefish, grouper, halibut, tilefish from the Atlantic Ocean, and albacore white tuna . A typical serving of fish for adults is 4 ounces before cooking. Serving sizes for children should be smaller and adjusted for their age and total calorie needs. Children should eat a variety of fish once or twice a week, according to the guideline. All fish contain at least some mercury, which can harm the brain and nervous system if consumed in high amounts over time. Children, pregnant or breast-feeding women, and women of childbearing age should avoid seven types of fish with higher mercury levels: tilefish from the Gulf of Mexico; shark; swordfish; orange roughly; bigeye tuna; marlin, and king mackerel.

SOURCE: HealthDay News, January 2017

Return to top

 
 
 GDM & Depression !

                                            Gestational Diabetes a Risk Factor for Postpartum Depression: Study

Gestational diabetes and a previous bout of depression can increase a first-time mother's risk of postpartum depression. The analysis of data from more than 700,000 women in Sweden showed that gestational diabetes alone raised the risk for postpartum depression. However, that risk rose even more if a woman had previously been diagnosed with depression. Most practitioners think of these as two isolated and very different conditions, but we now understand gestational diabetes and postpartum depression should be considered together, said lead researcher. While having diabetes increases risk for all women, for those women who have had a past depressive episode, having diabetes during pregnancy makes it 70 percent more likely that they will develop postpartum depression. The lead researcher also said they also identified other risk factors for postpartum depression. Among women with a history of depression, diabetes before pregnancy and giving birth prematurely at 32 to 36 weeks increased the risk, the researchers added. Also, among women with no history of depression, giving birth at a young age, having an instrument-assisted or cesarean delivery, and giving birth before 32 weeks increased the risk.

SOURCE: HealthDay News, January 2017

Return to top

 
 
Drugs & Stomach Infection !

                                                        Heartburn Drugs May Raise Risk of Stomach Infections: Study

People who take heartburn drugs such as Omeprazole or Esomeprazole may be at increased risk of two potentially serious gut infections, a new study suggests. The study, of nearly 565,000 adults, found those on certain heartburn drugs had higher risks of infection with C. difficile and Campylobacter bacteria. Both bugs cause abdominal pain and diarrhea, but can become more serious especially C. diff. All PPI suppress stomach acid production and make some people more vulnerable to gastrointestinal infections. The U.S. Food and Drug Administration have already warned about a risk of C. diff infection linked to proton pump inhibitors. Long-term use of PPIs, in particular, has been tied to a number of health risks, including nutrient deficiencies, bone loss and heart attack, lead researcher added. The new findings don't actually prove that either PPIs or H2 blockers raised the risk of gut infections. But it is plausible, according to the lead researcher. They suspect that drugs that suppress stomach acids can change the balance of "good" and "bad" bacteria in the gut, which may make people more susceptible to infections. For the study, lead researcher analyzed medical records from close to 565,000 Scottish adults. More than 188,000 had been given at least one prescription for a PPI or H2 blocker; the rest had no prescriptions for the drugs, lead researcher added. On average, people on the drugs were roughly four times more likely to develop a Campylobacter infection between 1999 and 2013.The other factors, such as people's age and medical history had an association between the heartburn medications and higher infection risks.

SOURCE: HealthDay News, January 2017

Return to top

 
 
Superbug !

                                                                    Superbug' Infections Down 30 Percent at VA Hospitals

Rates of a deadly "superbug" called methicillin-resistant Staphylococcus aureus, or MRSA, have dropped steadily at hospitals and long-term care health care facilities run by the U.S. Department of Veterans Affairs over the past eight years. Between 2007 and 2015, rates of monthly MRSA infections rates fell 37 percent in VA intensive care units. Infections in non-ICUs fell by about 30 percent, lead researcher added. Even larger reductions were seen in overall health care-acquired infections, which declined 80 percent or more in both ICUs and non-ICUs. Active surveillance was the primary driver of the downward trends seen in the VA. Understanding how and why rates of MRSA have diminished in recent years is essential for the continued progress of effective prevention programs. Staph bacteria, including MRSA, are one of the most common causes of health care-associated infections. MRSA doesn't respond to standard antibiotic treatment, and can lead to fatal pneumonia and bloodstream infections. Recommended guidelines included screening patients for MRSA at admission, transfer and discharge, implementing "contact precautions" for those carrying or infected with MRSA, ensuring adherence to hand hygiene, encouraging a change in staff thinking, making infection prevention a common goal. In September 2015, only two MRSA infections were reported in VA intensive care units. Twenty occurred in non-ICUs, including three in spinal cord injury units, according to the lead researcher. Health care-associated infections also occurred less frequently in the VA's long-term care facilities. In these locations, rates fell nearly 50 percent between July 2009 and September 2015. That final month, 31 MRSA cases were reported nationwide in long-term care places, the lead researcher found.

SOURCE: HealthDay News, January 2017

Return to top

 
 
Surgery & Obesity !

Weight-Loss Surgery Offers Long-Term Benefit to Very Obese Teens

Weight-loss surgery helps severely obese teens keep extra pounds off long-term. However, some young people may need additional surgery to manage complications associated with their rapid post-surgery weight loss. Some young patients may also develop nutritional deficiencies after their procedure. These are the first long-term follow-up studies on teens that undergo weight-loss surgery, top researcher added. The findings clearly document long-term benefits of adolescent bariatric treatment, but also highlight several nutritional risks.4.6 million children and teens in the United States are severely obese -- defined as roughly 100 pounds or more overweight. Severe obesity leads to poor health and quality of life, which is why many of these teens are offered the option to undergo weight-loss surgery, the top researcher added. Eight years after surgery, these patients had an average weight reduction of 30 percent. Nearly two-thirds of the teens remained obese, though not severely so. The study showed that only one patient dropped down to a normal weight. Among the teens that had weight-loss surgery, the number of those with diabetes, high cholesterol or high blood pressure dropped significantly. Along with these health benefits, however, 78 percent of the teens developed low levels of vitamin D, and 16 percent were deficient in vitamin B12. Mild anemia was diagnosed in 46 percent of these young people. These nutritional deficiencies could stem from the fact that the teens were simply eating less, or they may be absorbing nutrients less well, the lead researcher explained. Teens who had weight-loss surgery were hospitalized for an average of 6.5 days, while those who didn't have surgery were in the hospital for 1.5 days on average. Teens who'd undergone weight-loss surgeries also had an average of five extra visits to an outpatient clinic compared to those who hadn't had the operation.

SOURCE: HealthDay News, January 2017

Return to top

 
 

Products of SQUARE Pharmaceuticals Ltd.

  Product Mirakof®
  Generic Name Butamirate Citrate
  Strength 25 mg/5ml
  Dosage form Pediatric Drops
  Therapeutic Category Antitussive
  Product Ceftiben®
Generic Name

Ceftibuten

Strength 400 mg
Dosage form Capsule
Therapeutic Category Cephalosporin
  Product Nexum® MUPS
  Generic Name Esomeprazole
  Strength 20 mg
Dosage form Tablet
  Therapeutic Category Antiulcerant

Return to top

 

Copyright © 2017 SQUARE Pharmaceuticals Ltd. All rights reserved.